Prenetics Global Limited (PRE)
| Market Cap | 319.91M +230.8% |
| Revenue (ttm) | 120.07M +189.2% |
| Net Income | -50.42M |
| EPS | -3.35 |
| Shares Out | 16.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 124,272 |
| Open | 18.80 |
| Previous Close | 18.80 |
| Day's Range | 18.62 - 19.50 |
| 52-Week Range | 7.18 - 23.63 |
| Beta | 0.25 |
| Analysts | Strong Buy |
| Price Target | 34.20 (+79.91%) |
| Earnings Date | Aug 18, 2026 |
About PRE
Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
Financial Performance
In 2025, Prenetics Global's revenue was $92.39 million, an increase of 479.76% compared to the previous year's $15.94 million. Losses were -$37.71 million, -18.56% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for PRE stock is "Strong Buy." The 12-month stock price target is $34.2, which is an increase of 79.91% from the latest price.
News
Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation
Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation
Prenetics Global Registration statement: Registration filing
Prenetics Global filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Prenetics price target raised to $35 from $29 at Lake Street
Lake Street analyst Ryan Meyers raised the firm’s price target on Prenetics (PRE) to $35 from $29 and keeps a Buy rating on the shares. The structure of the $1B…
Prenetics price target raised to $40 from $30 at Benchmark
Benchmark raised the firm’s price target on Prenetics (PRE) to $40 from $30 and keeps a Buy rating on the shares after the company announced the closing of $1B in…
Prenetics' IM8 Secures $1 Billion Growth Financing from General Catalyst's Customer Value Fund (CVF)
IM8 is the fastest-growing premium supplement brand ever recorded — over 50 million servings delivered to date, with approximately 200,000 servings currently delivered daily, and an order every 27 sec...
Prenetics ups IM8 sales outlook amid growth financing, Bloomberg says
David Beckham and Prenetics (PRE)’ IM8 has lined up around $1B in growth financing from General Catalyst, Swetha Gopinath of Bloomberg reports, citing a statement. General Catalyst’s Customer Value Fu...
Prenetics Global Slides: Corporate presentation
Prenetics Global has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Prenetics initiated with a Buy at Benchmark
Benchmark initiated coverage of Prenetics (PRE) with a Buy rating and $30 price target The health and wellness company is focused on IM8, its consumer brand addressing the growing nutritional…
Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record ~$16.7 Million in May, Implying ~$200 Million in Annualized Recurring Revenue
Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million , up 23.1% from IM8 revenue of $27.4 million in Q4 2025 and nearly 6x year-over-year from IM8 revenue of $5.7 million in Q1 2025 Rais...
Prenetics Global Earnings release: Q1 2026
Prenetics Global released its Q1 2026 earnings on June 10, 2026, summarizing the period's financial results.
Prenetics Global Slides: Q1 2026
Prenetics Global has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on June 10, 2026.
MEXC SPACEX(PRE) Launchpad Subscriptions Exceed $173M Across Two Phases
Second phase of the SPACEX(PRE) Launchpad attracted over 36,000 users, with total subscription volume surpassing $117 million, subscription volume $173M
Prenetics Appoints Hudson Leogrande, Founder and CEO of Multi-Billion-Dollar DTC Brand Comfrt, to Board of Directors as IM8 Accelerates TikTok and Meta Expansion
Hudson Leogrande is the Founder and CEO of Comfrt — a multi-billion-dollar DTC brand projected to exceed $1 billion in revenue in 2026 Comfrt is one of the largest advertisers on both TikTok and Meta;...
MEXC SPACEX(PRE) Phase 2 Launchpad: 30% Off Subscription and Extra Airdrops for Stock Trading
SpaceX Launchpad's total subscription allocation has expanded to 7 million USDT, equivalent to 53,800 SPACE(PRE). The subscription price is set at 130 USDT
MEXC SPACEX(PRE) Launchpad Subscriptions Surpass $56 million, with the Offering Oversubscribed by Up to 15.5x
MEXC SPACEX(PRE) Launchpad is with total subscriptions surpassing $56 million and the most competitive pool reaching an oversubscription rate of 15.5x.
Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
Multi-year partnership lands as Prenetics' IM8 raises full-year 2026 revenue guidance to $190 million to $210 million following nearly 6x year-over-year growth in Q1 2026 Shetty is IM8's first global ...
Prenetics Global Earnings Call Transcript: Q1 2026
Q1 2026 revenue surged 334% year-over-year to $36M, driven by IM8's rapid growth and expanding margins. Guidance for 2026 IM8 revenue was raised to $190M-$210M, with new product launches and channel diversification representing further upside.
Prenetics Global Earnings release: Q1 2026
Prenetics Global released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Prenetics Global Slides: Q1 2026
Prenetics Global has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8
~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion
Prenetics Announces Preliminary Record Q1 2026 Results with IM8 Revenue Growing Nearly 6x YoY; Company Raises Full-Year 2026 IM8 Revenue Guidance to $190M–$210M
Prenetics records Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million , up 23.1% from IM8 revenue of $27.4 million in Q4 2025 Raises full-year 2026 IM8 revenue guidance to $190 million...
Prenetics to Report Q1 2026 Financial Results on May 14, 2026 and Host Earnings Conference Call
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with Davi...
Prenetics' IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership
NEW YORK and MIAMI, May 07, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), the parent company of IM8, the premium health and longevity brand co-founded...
Prenetics files to sell 2.36M Class A ordinary shares for holders
09:26 EDT Prenetics (PRE) files to sell 2.36M Class A ordinary shares for holders
Prenetics Global Registration statement: Registration filing
Prenetics Global filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.